<code id='63A3184457'></code><style id='63A3184457'></style>
    • <acronym id='63A3184457'></acronym>
      <center id='63A3184457'><center id='63A3184457'><tfoot id='63A3184457'></tfoot></center><abbr id='63A3184457'><dir id='63A3184457'><tfoot id='63A3184457'></tfoot><noframes id='63A3184457'>

    • <optgroup id='63A3184457'><strike id='63A3184457'><sup id='63A3184457'></sup></strike><code id='63A3184457'></code></optgroup>
        1. <b id='63A3184457'><label id='63A3184457'><select id='63A3184457'><dt id='63A3184457'><span id='63A3184457'></span></dt></select></label></b><u id='63A3184457'></u>
          <i id='63A3184457'><strike id='63A3184457'><tt id='63A3184457'><pre id='63A3184457'></pre></tt></strike></i>

          Home / Wikipedia / knowledge

          knowledge


          knowledge

          author:explore    Page View:355

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In